4-methyl-1-(p-tolyl)pentan-2-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-methyl-1-(p-tolyl)pentan-2-one
• 英文别名: 4-Methyl-1-p-tolyl-pentan-2-on；4-methyl-1-(4-toluyl)-pentan-2-one；4-methyl-1-(4-methylphenyl)pentan-2-one
• 化学式: C₁₃H₁₈O
• 分子量: 190.285
• InChiKey: BWQBRHDVGPMNOG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 kieselguhr 作用下， 450.0 ℃ 、2.0 kPa 条件下， 生成 4-methyl-1-(p-tolyl)pentan-2-one
  参考文献：
  名称：

  Ramart-Lucas; Guerlain, Bulletin de la Societe Chimique de France, 1931, vol. <4> 49, p. 1860,1867

  摘要：

  DOI：

文献信息

• Thianthrenation-Enabled α-Arylation of Carbonyl Compounds with Arenes
  作者：Xiao-Xue Nie、Yu-Hao Huang、Peng Wang

  DOI：10.1021/acs.orglett.0c02913

  日期：2020.10.2

  The Pd-catalyzed α-arylation of carbonyl compounds with simple arenes enabled by site-selective thianthrenation has been demonstrated. This one-pot process using thianthrenium salts as the traceless arylating reagents features mild conditions and a broad substrate scope. In addition, this protocol could also tolerate the heterocyclic carbonyl compounds and complex bioactive molecules, which is appealing

  已经证明了Pd催化的具有简单芳烃的羰基化合物的α-芳基化，可以通过位点选择性的thththrenation实现。使用th盐作为无痕芳基化试剂的一锅法工艺具有温和的条件和广泛的底物范围。另外，该方案还可以耐受杂环羰基化合物和复杂的生物活性分子，这对药物化学具有吸引力。
• Tetrahydroisoquinoline compound
  申请人：Kowa Company, Ltd.

  公开号：US08273766B2

  公开（公告）日：2012-09-25

  The present invention relates a specific tetrahydroisoquinoline compound which is useful as a chemokine receptor type 3 (CCR3) antagonist, and a pharmaceutical composition comprising the same as an active ingredient. The tetrahydroisoquinoline compound of the present invention is useful for the treatment or prevention of a disease in which CCR3 participates.

  本发明涉及一种特定的四氢异喹啉化合物，该化合物可作为趋化因子受体3（CCR3）拮抗剂，并且包含该化合物作为活性成分的药物组合物。本发明的四氢异喹啉化合物可用于治疗或预防CCR3参与的疾病。
• PYRIDO[4,3-B]INDOLES AND METHODS OF USE
  申请人：Medivation Technologies, Inc.

  公开号：US20130184304A1

  公开（公告）日：2013-07-18

  This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[4,3-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本公开涉及新的杂环化合物，可用于调节个体中的组胺受体。描述了吡啶并[4,3-b]吲哚，以及包含这些化合物的药物组合物和使用这些化合物进行各种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
• TETRAHYDROISOQUINOLINE COMPOUND
  申请人：Kowa Company, Ltd.

  公开号：EP2143714B1

  公开（公告）日：2013-06-05
• COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR
  申请人：RYDER Sean

  公开号：US20110065704A1

  公开（公告）日：2011-03-17

  The invention relates to compositions and methods for inhibiting RNA binding proteins (e.g., MEX-3, MEX-5 and POS-1), as well as methods for treating and preventing disorders associated with parasitic infections and inflammatory disorders.